Hepatitis B, Chronic
Information
- Disease name
- Hepatitis B, Chronic
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05612581 | Active, not recruiting | Phase 1/Phase 2 | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection | May 10, 2023 | March 2027 |
| NCT06000657 | Active, not recruiting | Phase 4 | The Efficacy and Safety of Switching to Vemliver Tab From Entecavir in Chronic Hepatitis B Patients Who Pretreated With Entecavir | August 28, 2023 | December 31, 2025 |
| NCT05473806 | Active, not recruiting | Phase 4 | Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes | September 18, 2020 | February 19, 2023 |
| NCT05276297 | Active, not recruiting | Phase 2 | A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy | March 22, 2022 | February 11, 2026 |
| NCT05275023 | Active, not recruiting | Phase 2 | An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants | June 30, 2022 | May 30, 2024 |
| NCT05123599 | Active, not recruiting | Phase 1 | A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection | December 6, 2021 | August 2, 2024 |
| NCT02766933 | Active, not recruiting | Cameroon Baptist Convention Health Board Chronic Hepatitis B Cohort Study | May 2016 | December 2024 | |
| NCT05630807 | Active, not recruiting | Phase 3 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) | December 7, 2022 | May 8, 2026 |
| NCT04782375 | Active, not recruiting | Phase 4 | Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B | September 1, 2021 | December 2024 |
| NCT05630820 | Active, not recruiting | Phase 3 | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) | December 6, 2022 | May 8, 2026 |
| NCT04225715 | Active, not recruiting | Phase 2 | A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B | July 5, 2020 | January 31, 2025 |
| NCT03866187 | Active, not recruiting | Phase 1/Phase 2 | Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection | March 28, 2019 | October 31, 2025 |
| NCT00435825 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB). | March 2007 | December 2010 |
| NCT00436163 | Completed | Phase 4 | A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B | March 2007 | May 2010 |
| NCT00442572 | Completed | Phase 2 | SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB). | July 3, 2006 | April 23, 2012 |
| NCT00487747 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B. | August 2006 | October 2009 |
| NCT00512941 | Completed | Laboratory Profile of Hepatitis B and C in Users of a Reference Service | June 2007 | August 2007 | |
| NCT00536263 | Completed | Phase 3 | PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327) | September 2007 | November 2009 |
| NCT00537537 | Completed | Phase 4 | To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB) | August 2007 | |
| NCT00614471 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B. | August 2007 | October 2009 |
| NCT00625339 | Completed | Phase 4 | Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA | February 2008 | November 2010 |
| NCT00625560 | Completed | Phase 4 | Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA | February 2008 | November 2010 |
| NCT00637663 | Completed | Phase 4 | Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA | February 2008 | November 2010 |
| NCT00640588 | Completed | Phase 3 | Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine | March 2008 | December 2009 |
| NCT00646503 | Completed | Phase 4 | Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B | March 2008 | September 2009 |
| NCT00651209 | Completed | Phase 4 | A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB) | February 2008 | |
| NCT00661076 | Completed | Phase 3 | ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B | August 2008 | May 2011 |
| NCT00686790 | Completed | Phase 3 | Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) | December 2005 | May 2009 |
| NCT00718887 | Completed | Phase 4 | Suboptimal Responders to Adefovir Switching to Entecavir | July 2008 | January 2011 |
| NCT00838071 | Completed | Phase 3 | Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation | October 2003 | August 2004 |
| NCT00895713 | Completed | Phase 2 | Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation | November 2004 | July 2005 |
| NCT00922207 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B | May 7, 2010 | September 29, 2014 |
| NCT00927082 | Completed | Phase 4 | A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B | April 2009 | November 2014 |
| NCT00940485 | Completed | Phase 4 | A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B | April 2009 | December 2011 |
| NCT00962533 | Completed | Phase 4 | EFFicacy Optimization Research of Telbivudine Therapy | August 2009 | August 2012 |
| NCT00962871 | Completed | Phase 1 | A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both | August 2009 | February 2012 |
| NCT00962975 | Completed | Phase 1 | A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies | September 2009 | May 2013 |
| NCT01011738 | Completed | An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys | April 11, 2009 | November 18, 2014 | |
| NCT01013272 | Completed | N/A | Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load | June 2007 | July 2010 |
| NCT01023217 | Completed | Phase 4 | Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir | November 2009 | September 2012 |
| NCT01023230 | Completed | Phase 1 | A Study to Assess DV-601 in Subjects With Chronic Hepatitis B | September 2009 | May 2011 |
| NCT01086085 | Completed | Phase 4 | A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive | April 2010 | March 2013 |
| NCT01155427 | Completed | Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB) | May 2009 | April 2010 | |
| NCT00076336 | Completed | Phase 3 | Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis | December 2003 | |
| NCT00111943 | Completed | Phase 2 | Safety and Acceptability of a Vaginal Microbicide | October 2007 | |
| NCT00120354 | Completed | Phase 4 | Long-Term Lamivudine Therapy for Chronic Hepatitis B | July 11, 2005 | March 31, 2007 |
| NCT00230503 | Completed | Phase 2 | Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B | June 2004 | December 2006 |
| NCT00347009 | Completed | Phase 4 | Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis | May 2005 | September 2009 |
| NCT00363155 | Completed | Phase 1/Phase 2 | KRN7000 in Chronic Hepatitis B | March 2003 | July 2006 |
| NCT00395018 | Completed | Phase 3 | Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection | April 2007 | March 2011 |
| NCT00403585 | Completed | Phase 4 | Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814 | July 2006 | April 2008 |
| NCT00410072 | Completed | Phase 3 | Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B | April 2007 | October 2010 |
| NCT00410202 | Completed | Phase 3 | Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus | March 2008 | July 2012 |
| NCT00423891 | Completed | Phase 1/Phase 2 | A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection | June 30, 2007 | September 4, 2017 |
| NCT01095835 | Completed | Phase 3 | A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV) | February 2005 | January 2010 |
| NCT01107483 | Completed | Observe Change of Endotoxaemia and Related Mediators in Patients With Chronic Hepatitis B Virus (HBV) Infection | December 2009 | March 2010 | |
| NCT01128686 | Completed | Lamivudine(LAM) Good Responder Study | August 2010 | June 2011 | |
| NCT00034359 | Completed | Phase 2 | Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection | February 2002 | January 2003 |
| NCT01163240 | Completed | Epidemiological Study in Children and Adolescents With Chronic Hepatitis B | June 2009 | ||
| NCT01205165 | Completed | Phase 4 | An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB) | December 17, 2004 | April 28, 2006 |
| NCT01237496 | Completed | Phase 3 | Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253 | July 2005 | September 2009 |
| NCT01283074 | Completed | An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas) | May 2009 | November 2012 | |
| NCT01311947 | Completed | Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B | March 2011 | March 2012 | |
| NCT01353742 | Completed | Phase 1 | Lamivudine and Adefovir Dipivoxil Fixed Dose Combination | February 21, 2011 | April 12, 2011 |
| NCT01356901 | Completed | Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients | January 2011 | January 2015 | |
| NCT01376154 | Completed | Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis) | June 2006 | February 2011 | |
| NCT01475851 | Completed | Phase 3 | Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs | December 2011 | October 2014 |
| NCT01480284 | Completed | Phase 3 | Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue | November 2011 | November 2014 |
| NCT01480622 | Completed | Phase 1 | Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects | December 5, 2011 | December 30, 2011 |
| NCT01519921 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. | October 2005 | June 2008 |
| NCT01519960 | Completed | Phase 3 | A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B | July 11, 2012 | October 18, 2021 |
| NCT01521975 | Completed | Phase 4 | A Two-year Study of Telbivudine in HBeAg Negative Hepatitis | January 1, 2011 | May 30, 2014 |
| NCT01641536 | Completed | Phase 1 | Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients | November 2011 | April 2013 |
| NCT01645969 | Completed | A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265 | April 2011 | October 2012 | |
| NCT01667432 | Completed | An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B | July 8, 2011 | August 12, 2014 | |
| NCT01697501 | Completed | Phase 3 | A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253 | November 8, 2012 | June 21, 2013 |
| NCT01705704 | Completed | A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B | June 2012 | February 2013 | |
| NCT01706575 | Completed | Phase 2 | A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression | January 2013 | November 2014 |
| NCT01730508 | Completed | An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B | November 20, 2012 | June 25, 2017 | |
| NCT01734018 | Completed | An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B | August 2011 | August 2012 | |
| NCT01787279 | Completed | Phase 4 | An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B | January 2006 | May 2009 |
| NCT01855997 | Completed | A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue | August 20, 2013 | November 28, 2014 | |
| NCT01908660 | Completed | Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions | January 2007 | October 2015 | |
| NCT02075294 | Completed | Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B | January 2010 | October 2012 | |
| NCT02081469 | Completed | Phase 4 | Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy | March 17, 2014 | August 5, 2019 |
| NCT02097004 | Completed | Phase 4 | Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection | April 2014 | March 13, 2018 |
| NCT02129829 | Completed | PROLIFICA - West African Treatment Cohort for Hepatitis B | October 2011 | July 31, 2018 | |
| NCT02167113 | Completed | Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay | March 2014 | January 23, 2018 | |
| NCT02195518 | Completed | Phase 4 | Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study | March 18, 2015 | August 14, 2018 |
| NCT02201407 | Completed | An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study | December 18, 2014 | April 10, 2017 | |
| NCT02224456 | Completed | Phase 4 | Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis | March 25, 2015 | December 4, 2020 |
| NCT02338674 | Completed | Phase 1/Phase 2 | TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction | October 2014 | October 2017 |
| NCT02360592 | Completed | Phase 4 | Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients | June 2013 | April 2017 |
| NCT02366208 | Completed | Phase 2 | Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B | May 2011 | August 2013 |
| NCT02391805 | Completed | Phase 2 | A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection | May 17, 2015 | October 16, 2017 |
| NCT02499562 | Completed | Phase 2 | A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis | June 25, 2015 | November 20, 2020 |
| NCT02570191 | Completed | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV) | November 2004 | February 2007 |
| NCT02598063 | Completed | Phase 4 | A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B | October 2005 | April 2009 |
| NCT02600117 | Completed | Phase 3 | Use of TDF in Patients With Inactive Chronic Hepatitis B Infection | January 26, 2016 | February 28, 2023 |
| NCT02604823 | Completed | Phase 4 | A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV) | November 2003 | November 2005 |
| NCT02631096 | Completed | Phase 2 | Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy | December 2015 | May 18, 2018 |
| NCT02646163 | Completed | Phase 1/Phase 2 | Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients | January 2009 | December 2012 |
| NCT02646189 | Completed | Phase 1/Phase 2 | Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients | August 2011 | August 2013 |
| NCT02693652 | Completed | Phase 1/Phase 2 | A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine | October 28, 2014 | August 22, 2017 |
| NCT02726789 | Completed | Phase 2 | Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B | October 2012 | December 2016 |
| NCT02791269 | Completed | Phase 4 | A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program | January 2006 | July 2008 |
| NCT02876419 | Completed | A Long Term Follow-up Study of Patients From the REP 301 Protocol | August 2016 | December 2019 | |
| NCT02952924 | Completed | Phase 1 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants | December 14, 2016 | March 16, 2022 |
| NCT02956850 | Completed | Phase 1 | A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531 | December 12, 2016 | June 15, 2021 |
| NCT03258710 | Completed | Phase 4 | A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B | October 2, 2017 | November 25, 2019 |
| NCT03272009 | Completed | Phase 1 | Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects | September 21, 2017 | July 30, 2018 |
| NCT03300414 | Completed | Biologic Basis of Liver Cancer From Chronic Hepatitis B | March 20, 2017 | December 14, 2018 | |
| NCT03320616 | Completed | Phase 1 | EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection | February 10, 2017 | October 12, 2017 |
| NCT03350074 | Completed | HBV Envelope Proteins Variability on HBs Antigen Clearance Under Nucleos(t)Ide Analogue Therapy | November 5, 2013 | September 1, 2017 | |
| NCT03463369 | Completed | Phase 1 | A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed | April 18, 2018 | March 23, 2021 |
| NCT03468907 | Completed | Phase 4 | The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation | June 1, 2015 | December 31, 2017 |
| NCT03469583 | Completed | Phase 1 | Drug Drug Interaction Study for EYP001 With Entecavir | February 12, 2018 | July 20, 2018 |
| NCT03471624 | Completed | Phase 4 | Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF) | May 1, 2018 | April 19, 2022 |
| NCT03485534 | Completed | Phase 4 | Evaluate the Efficacy and Safety to Tenofovir Disoproxil in Chronic Hepatitis B Patients | January 23, 2018 | November 4, 2019 |
| NCT03681132 | Completed | Phase 4 | The Norwegian Nucleoside Analogue Stop Study | September 20, 2018 | January 31, 2023 |
| NCT03772249 | Completed | Phase 1 | Study of Safety and Tolerability of DCR HBVS | December 28, 2018 | July 12, 2022 |
| NCT03778567 | Completed | Phase 4 | Renoprotective Effects of Telbivudine in Chronic Hepatitis B | August 1, 2013 | May 31, 2018 |
| NCT03977857 | Completed | Prediction Model Based on Computed Tomography Liver Volume for the Short-term Mortality in Hepatitis B Related Acute-on-Chronic | March 1, 2019 | December 31, 2019 | |
| NCT03982186 | Completed | Phase 2 | A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection | August 1, 2019 | April 26, 2022 |
| NCT04082338 | Completed | N/A | Chronic HBV Management for Asian American | April 1, 2019 | March 31, 2022 |
| NCT04129554 | Completed | Phase 2 | A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection | November 6, 2019 | June 9, 2022 |
| NCT04248426 | Completed | Phase 1 | A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection | February 5, 2020 | May 18, 2021 |
| NCT04289987 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine | February 19, 2020 | December 4, 2023 |
| NCT04365933 | Completed | Phase 2 | A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir | May 25, 2020 | November 29, 2021 |
| NCT04426968 | Completed | Phase 2 | A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B | June 18, 2021 | November 29, 2023 |
| NCT04439539 | Completed | Phase 2 | A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection | September 14, 2020 | February 13, 2024 |
| NCT04507269 | Completed | Phase 2 | Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China | August 18, 2020 | September 30, 2021 |
| NCT04667104 | Completed | Phase 2 | A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection | February 1, 2021 | April 17, 2023 |
| NCT04749368 | Completed | Phase 2 | Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection | April 12, 2021 | July 4, 2023 |
| NCT05107778 | Completed | Phase 2 | Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV | January 10, 2022 | December 14, 2023 |
| NCT05242445 | Completed | Phase 1 | A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection | April 19, 2022 | May 9, 2023 |
| NCT05265026 | Completed | N/A | Aerobic Exercise Training in Patients With Chronic Hepatitis B and Hepatic Steatosis | March 14, 2022 | October 1, 2023 |
| NCT05391360 | Completed | Phase 1 | Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study | October 11, 2021 | January 17, 2023 |
| NCT05470829 | Completed | Phase 1 | A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R | May 27, 2021 | November 17, 2021 |
| NCT06452693 | Not yet recruiting | Phase 1/Phase 2 | A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B | June 2024 | September 2026 |
| NCT05328427 | Not yet recruiting | N/A | Discontinuation of Antiviral Therapy as a Strategy to Cure Hepatitis B | May 15, 2022 | December 31, 2025 |
| NCT06041022 | Not yet recruiting | A Non-invasive Model to Predict Antiviral Therapy in Gray Zone of Chronic Hepatitis B | October 1, 2023 | December 31, 2023 | |
| NCT05045261 | Recruiting | Phase 2 | ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC Discontinuation | February 1, 2022 | June 30, 2024 |
| NCT04035837 | Recruiting | Phase 4 | The Clinical Cure Project of Chronic Hepatitis B in China | May 16, 2018 | June 30, 2024 |
| NCT04166266 | Recruiting | Observatory of Efficacy and Safety of Bulevirtide in Patients With Chronic HBV/HDV Co-infection | February 19, 2020 | September 30, 2027 | |
| NCT05708560 | Recruiting | Relationship Between MAFLD and Liver Fibrosis Progression in Patients With Chronic Hepatitis B: a Multicenter Retrospective Cohort Study | March 1, 2022 | January 31, 2023 | |
| NCT05376124 | Recruiting | Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory | January 1, 2022 | December 31, 2025 | |
| NCT04856085 | Recruiting | Phase 2 | Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection | July 11, 2021 | June 2027 |
| NCT04780204 | Recruiting | Phase 4 | Effectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels | August 23, 2021 | December 2026 |
| NCT05382013 | Recruiting | Phase 4 | Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment | April 27, 2022 | April 30, 2024 |
| NCT06245291 | Recruiting | Phase 2 | Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection | May 1, 2024 | July 2027 |
| NCT05182463 | Recruiting | Phase 4 | Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients | January 8, 2022 | November 30, 2029 |
| NCT06216470 | Recruiting | Phase 2 | Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION] | March 13, 2024 | December 2029 |
| NCT06023745 | Recruiting | Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. | July 20, 2023 | September 2023 | |
| NCT04585165 | Recruiting | User-friendly HIV Testing and Counseling Services | October 19, 2020 | December 2024 | |
| NCT06196632 | Recruiting | Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Therapy | January 6, 2024 | December 31, 2025 | |
| NCT05172453 | Recruiting | Mother-to-child Transmission of HBV in China | July 1, 2015 | December 31, 2025 | |
| NCT06115993 | Recruiting | Phase 1 | A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and Chronic Hepatitis B Patients | August 3, 2023 | October 2024 |
| NCT05867056 | Recruiting | Phase 1 | Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection | August 12, 2020 | December 15, 2024 |
| NCT05484466 | Recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB | November 11, 2022 | December 30, 2024 |
| NCT05977283 | Recruiting | HBsAg Declined Patients Follow-up Study | May 11, 2023 | March 2028 | |
| NCT05937178 | Recruiting | Real-world Study Optimizing Nucleotide-analogues | January 31, 2023 | January 31, 2029 | |
| NCT05922306 | Recruiting | Early Phase 1 | Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B | July 2023 | December 2027 |
| NCT05870969 | Recruiting | Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH) | March 1, 2023 | March 2028 | |
| NCT04536532 | Suspended | Phase 1/Phase 2 | Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study | October 12, 2020 | December 30, 2023 |
| NCT04684914 | Terminated | Phase 2 | HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) | December 26, 2020 | April 17, 2024 |
| NCT03164889 | Terminated | N/A | Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients | January 2017 | December 1, 2021 |
| NCT05423106 | Terminated | Phase 1 | A Single and Multiple Ascending Dose Study of JNJ-64457744 | July 4, 2022 | March 20, 2023 |
| NCT03932513 | Terminated | Phase 2 | Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients | April 11, 2019 | December 21, 2019 |
| NCT01341106 | Terminated | Phase 4 | Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection | April 2011 | April 2015 |
| NCT00460850 | Terminated | Phase 4 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B. | September 2007 | June 2008 |
| NCT04023721 | Terminated | Phase 2 | Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor | June 18, 2019 | July 16, 2020 |
| NCT04059198 | Terminated | Phase 2 | Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus | October 10, 2019 | April 2, 2020 |
| NCT00230490 | Terminated | Phase 2 | Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201 | June 2005 | May 2007 |
| NCT01641926 | Terminated | Phase 3 | A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450) | November 26, 2012 | January 21, 2016 |
| NCT01794234 | Terminated | An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues | August 2012 | September 2013 | |
| NCT01886300 | Terminated | An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam | September 2012 | May 2013 | |
| NCT04465916 | Terminated | Phase 2 | Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD) | May 12, 2020 | November 25, 2021 |
| NCT02065336 | Terminated | Phase 2 | A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection | March 2014 | January 2017 |
| NCT02128503 | Terminated | N/A | Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease | February 2013 | October 16, 2015 |
| NCT02498275 | Terminated | Effect of RO6871765 and RO7011785 on Immune Response With the Stimulation of Peripheral Blood Mononuclear Cells (PBMCs) in Chinese Healthy Volunteers and Chronic Hepatitis B Patients | July 2014 | August 2014 | |
| NCT04847440 | Terminated | Phase 2 | A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection | March 30, 2021 | September 1, 2022 |
| NCT05005507 | Terminated | Phase 2 | A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection | November 3, 2021 | December 29, 2021 |
| NCT02604355 | Terminated | Phase 1 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients | November 28, 2015 | May 9, 2016 |
| NCT02826018 | Terminated | Phase 1 | A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection | June 24, 2016 | October 2017 |
| NCT02605252 | Unknown status | N/A | New Strategy Study of Functional Cure of Chronic Hepatitis B | March 2016 | |
| NCT01220596 | Unknown status | Phase 3 | Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B. | June 2010 | June 2013 |
| NCT01456312 | Unknown status | Phase 4 | HBsAg Related Response Guided Therapy | September 2012 | August 2016 |
| NCT00810524 | Unknown status | Phase 4 | Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection | January 2007 | January 2017 |
| NCT04201808 | Unknown status | Phase 4 | Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides | May 1, 2021 | September 30, 2023 |
| NCT04211805 | Unknown status | Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B | January 27, 2020 | September 30, 2021 | |
| NCT00917761 | Unknown status | Phase 4 | Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B | February 2007 | December 2013 |
| NCT04237376 | Unknown status | Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Vertical Transmission | April 9, 2019 | September 30, 2020 | |
| NCT00823550 | Unknown status | Phase 4 | Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients | January 2009 | July 2015 |
| NCT05168293 | Unknown status | Effect of Entecavir Versus Tenofovir on HBV DNA Level in Peripheral Blood Mononuclear Cells | February 1, 2022 | May 1, 2023 | |
| NCT02719808 | Unknown status | Study of Antiretroviral Therapy to Prevent HBV Intrauterine Infection | March 2015 | December 2022 | |
| NCT00815464 | Unknown status | N/A | A Single-Arm Study Evaluating the Efficacy of Liquid Acupuncture Therapeutics in Chronic Hepatitis B | March 2009 | March 2010 |
| NCT00154869 | Unknown status | Phase 3 | Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C | June 2004 | August 2007 |
| NCT03759782 | Unknown status | Phase 3 | Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity | January 10, 2019 | September 30, 2022 |
| NCT04538651 | Unknown status | A Cross-sectional Study for Renal Function of Patients With Chronic Hepatitis B in China | August 31, 2020 | August 31, 2021 | |
| NCT02148562 | Unknown status | Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity | April 2014 | December 2017 | |
| NCT04597164 | Unknown status | Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF | December 22, 2020 | September 30, 2023 | |
| NCT03539016 | Unknown status | Observational Study on Pregnant Women With Chronic Hepatitis B and Their Infants | July 2015 | May 2018 | |
| NCT01090531 | Unknown status | Patients With Chronic Hepatitis B and Low Viremia Not Receiving Antiviral Therapy | August 2009 | August 2021 | |
| NCT04724785 | Unknown status | Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients | December 1, 2020 | December 31, 2022 | |
| NCT02267473 | Unknown status | Hepatitis B Patients Under Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function | October 2014 | December 2020 | |
| NCT02327416 | Unknown status | Phase 3 | A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study) | October 2014 | June 2019 |
| NCT02327663 | Unknown status | Phase 4 | Emtricitabine for Naive Chinese Chronic Hepatitis B Patients | December 2014 | December 2017 |
| NCT02327676 | Unknown status | Phase 4 | Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients | January 2015 | July 2016 |
| NCT02327689 | Unknown status | Phase 4 | Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients | January 2015 | July 2017 |
| NCT02327702 | Unknown status | Phase 4 | Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients | January 2015 | July 2017 |
| NCT02327715 | Unknown status | Phase 4 | Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients | January 2015 | July 2016 |
| NCT05398393 | Unknown status | N/A | An Experimental Study on the Effect of Tenofovir Amibufenamide on Blood Lipid During Anti-HBV Treatment | January 1, 2022 | June 30, 2023 |
| NCT03459768 | Unknown status | Cohort Study on People Who Inject Drugs in Senegal | August 24, 2016 | June 30, 2021 | |
| NCT00860626 | Unknown status | N/A | Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B | January 2008 | February 2010 |
| NCT02366247 | Unknown status | Phase 3 | Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B | August 2013 | February 2016 |
| NCT04805034 | Unknown status | Predictive Model for Prognosis of Chronic HBV Infection Mothers | April 16, 2021 | January 31, 2024 | |
| NCT02392598 | Unknown status | A Hepatitis B With Hepatic Steatosis Study | August 2015 | December 2020 | |
| NCT02482272 | Unknown status | Phase 4 | Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B | May 2015 | May 2017 |
| NCT05177926 | Unknown status | Phase 4 | Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF) | April 4, 2021 | December 31, 2023 |
| NCT02974829 | Unknown status | REALM China Extension Study | May 2016 | ||
| NCT02510963 | Unknown status | N/A | Optimal Time for Tenofovir Treatment of Anti-Hepatitis B Virus (HBV) During the Pregnancy | November 2015 | August 2017 |
| NCT03358108 | Unknown status | A Prospective,Observational Follow-up Study of Nucleoside Treated Patients With Chronic Hepatitis B (OCEAN Study) | February 27, 2018 | December 1, 2022 | |
| NCT02588937 | Unknown status | Phase 4 | Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients | October 2015 | June 2017 |
| NCT04886102 | Unknown status | Molecular Epidemiology of Hepatitis B in Cayenne General Hospital, French Guiana | February 11, 2021 | February 1, 2022 | |
| NCT02826070 | Unknown status | Phase 4 | EFFORT Further Extension Study | April 2015 | October 2017 |
| NCT05286216 | Unknown status | N/A | The Effect of Education on Drug Compliance and Quality of Life in Hepatitis B Patients | April 15, 2022 | December 25, 2022 |
| NCT00921180 | Unknown status | Phase 4 | Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B | February 2007 | December 2013 |
| NCT05057065 | Unknown status | A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB | September 15, 2021 | June 1, 2023 | |
| NCT04070079 | Unknown status | Phase 4 | Tenofovir Alafenamide With Fine Needle Aspiration Biopsy in Chronic Hepatitis B: | January 29, 2019 | December 31, 2022 |
| NCT04133259 | Unknown status | Phase 2 | Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients | December 31, 2019 | July 30, 2022 |
| NCT04160897 | Unknown status | Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis | October 22, 2019 | October 31, 2020 | |
| NCT01529255 | Unknown status | Phase 4 | EFFORT Extension Study | August 2011 | December 2015 |
| NCT05550519 | Withdrawn | Early Phase 1 | A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment | October 31, 2022 | August 28, 2025 |
| NCT00800787 | Withdrawn | Phase 3 | Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation | April 2010 | September 2010 |
| NCT01179594 | Withdrawn | Phase 4 | A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B. | September 18, 2010 | November 2014 |
| NCT03125213 | Withdrawn | Phase 2 | A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects | September 12, 2017 | February 15, 2019 |
| NCT00710216 | Withdrawn | Phase 4 | Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B | ||
| NCT00986778 | Withdrawn | Phase 4 | Entecavir Plus Adefovir in Lamivudine-Resistant Patients | December 2009 | June 2014 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D019694